<DOC>
	<DOCNO>NCT00990704</DOCNO>
	<brief_summary>This study exploratory comparison efficacy safety paricalcitol injection maxacalcitol injection chronic kidney disease participant receive hemodialysis secondary hyperparathyroidism .</brief_summary>
	<brief_title>Paricalcitol Compared Maxacalcitol Chronic Kidney Disease Patients With Secondary Hyperparathyroidism</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcitriol</mesh_term>
	<mesh_term>Maxacalcitol</mesh_term>
	<criteria>Chronic kidney disease ( CKD ) patient iPTH &gt; =300 pg/mL , adjust calcium &gt; =8.4 &lt; 10.2 mg/dL , phosphorus &lt; =6.5 mg/dL Patients receive dialysis 3 time weekly least 3 month inform consent obtain schedule receive hemodialysis study period Patients use dialysate constant concentration calcium 4 week inform consent obtain receive phosphate binder constant dose regimen 2 week inform consent obtain Patients take drug affect iPTH , calcium , bone metabolism Patients history allergic reaction significant sensitivity vitamin D Patients receive parathyroidectomy ethanol infusion within 1 year inform consent obtain Patients malignancy clinically significant hepatic disease ( liver function test 3 time upper limit normal ) refractory hepatic disease Patients cardiovascular disease designate New York Heart Association Class III IV follow cardiovascular cerebrovascular disease within 6 month inform consent obtain : Acute coronary syndrome ( myocardial infarction unstable angina ) acute cerebral vascular disease ( cerebral infarction cerebral hemorrhage ) Coronary arterial revascularization ( coronary artery bypass grafting , percutaneous transluminal coronary angioplasty ) Cerebral arterial revascularization ( cerebral aneurysm clipping , cerebral aneurysm embolization , carotid artery endarterectomy ) Arteriosclerosis obliterans rest pain ( Fontaine classification III severe ) Patients severe hypertension ( define mean rest blood pressure take patient supine position dialysis 6 dialysis session inform consent obtain : systolic &gt; = 180 mmHg diastolic &gt; = 110 mmHg ) Patients uncontrolled diabetes mellitus ( defined mean glycosylated hemoglobin &gt; =8 % 3 month inform consent obtain ) Patients history drug alcohol abuse within 6 month inform consent obtain Patients require chronic use cytochrome P450 ( CYP3A ) inhibitor inducer Patients take product contain aluminum 2 week inform consent obtain Patients take paricalcitol past</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Secondary hyperparathyroidism</keyword>
	<keyword>Hemodialysis</keyword>
	<keyword>paricalcitol</keyword>
	<keyword>maxacalcitol</keyword>
</DOC>